Science

Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study

Herbert Loong/immunooncologyindia.com

Apr 7, 2025, 11:42

Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study

Herbert Loong, Chair-Elect of the International Affairs Committee at American Society of Clinical Oncology (ASCO), shared an article by A.C. Chiang, et al. on LinkedIn:

“Happy to share our recent ESMO Open paper on the safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy.

Luis Paz-Ares, Noemi Reguart, Shirish Gadgeel and others.”

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.

Authors: A.C. Chiang, et al.

Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study

American Society of Clinical Oncology ASCO cancer DeLLphi300 ESMO Open fight against cancer Global fight against cancer Herbert Loong Luis Paz-Ares Noemi Reguart OncoDaily Oncology Shirish Gadgeel Tarlatamab

Douglas Flora: Fighting Cancer with Heart

Eric Small: Deeply Honored to Step Into the Role of 2025-26 ASCO President

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025